Jolt VC

Jolt VC provides syndicate LPs with unparalleled access to premier pre-seed and seed stage investment opportunities, focusing on groundbreaking companies at the intersection of two or more transformative tech frontiers: (i) next-gen biotech (inc. synbio), (ii) AI/ML, (iii) space-tech, and (iv) overlooked demographic trends. Our portfolio includes several breakout partner-companies operating at these dynamic intersections: Ataraxis (ii+iv), Charter Space (ii+iii), Conception Bio (i+iv), Endogene (i+iv), Faro Quantum (ii+iii), Fauna Bio (i+iii), General Proximity (i+iv), KiraGen Bio (i+ii), Lime Therapeutics (i+ii), Siren Biotechnology (i+ii), Solideon (ii+iii), Spark Neuro (i+ii), and Turn Biotechnologies (i+iv). Jolt’s robust founder network and thorough due diligence ethos stem from the extensive experience of its Founding GP's career in financial advisor roles (inc. Blackstone), investment roles (inc. 2048 VC), and executive roles across biotech, health tech, SAAS, fintech, and IP-heavy next-gen industrials. With over a decade in major angel investing and mentoring ecosystems, Jolt VC partners bring a wealth of knowledge and strategic insight to every investment opportunity. For the syndicate to invest, founders and companies must present a well-defined deep-tech business model and a defensible moat, both of which are subject to rigorous due diligence. Jolt VC partners remain actively engaged with LPs in diligence, ensuring transparency and confidence in each investment decision. By combining an expert understanding of emerging technologies with a disciplined investment approach, Jolt VC is positioned to nurture the next wave of tech leaders, driving innovations that will define the 21st century.